TALENT Biotechs develops cannabidiol-based therapies.TALENT screens and locates pharmaceutical and medical technologies patented in the global market and leverages the development process of research and clinical trials throughPhase II into a Phase IIIstarting point. TALENThas suggestedthe use of cannabidiol for the prevention and treatment of graft-versus-host disease, which is a major cause of morbidity and mortality withallogeneic hematopoietic stem cell transplantation. TALENT Biotechs has been acquired by Kalytera Therapeutics, Beverly, Massachusetts, United States.